Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Immunologic dysfunction in cancer

D Y Kavanaugh¹, D P Carbone

¹Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA.

Hematology/Oncology Clinics of North America

|August 1, 1996

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA.

ESMO open·2025

Same author

Vaping, Smoking and Lung Cancer Risk.

Journal of oncology research and therapy·2024

Same author

Genomic characterization of thymic epithelial tumors in a real-world dataset.

ESMO open·2023

Same author

Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].

ESMO open·2021

Same author

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

ESMO open·2021

Same author

Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026

Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026

See all related articles

Tumors disrupt the immune system, impairing the body's natural defenses. Understanding tumor immune evasion mechanisms is key to developing new cancer immunotherapies and preventing tumor growth.

Area of Science:

Immunology
Oncology
Cancer Research

Background:

Tumor presence complexly affects host immune system functions.
Immune induction and action processes are compromised in cancer patients.
Tumor-induced immunosuppression hinders effective anti-tumor responses.

Purpose of the Study:

To analyze molecular mechanisms of tumor immune evasion.
To explore novel strategies for preventing T-cell immunosuppression in cancer.
To develop new immunotherapeutic approaches for cancer treatment.

Main Methods:

Molecular analysis of tumor-host interactions.
Investigating immune surveillance escape mechanisms.
Evaluating strategies to counteract tumor-induced immunosuppression.

Related Experiment Videos

Main Results:

Identified key mechanisms of tumor immune evasion.
Highlighted the broad impact of tumors on immune responses.
Provided insights into potential therapeutic targets.

Conclusions:

Understanding tumor immune evasion is crucial for cancer therapy.
Novel immunotherapies can be developed by targeting these mechanisms.
Preventing immunosuppression may halt tumor progression or development.